Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Irinotecan (Primary) ; Irinotecan (Primary) ; Pazopanib (Primary) ; Temozolomide (Primary)
- Indications Ewing's sarcoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms PAZIT
- 24 Jun 2019 Planned number of patients changed from 18 to 32.
- 06 Mar 2019 Planned End Date changed from 30 Nov 2019 to 30 Jun 2021.
- 06 Mar 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Jun 2020.